SHR4640

The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment

Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers

Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers

The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout

Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia

A Single Dose Study of SHR4640 in Healthy Male Volunteers

Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level

Multiple Dose Study of SHR4640 in Healthy Subjects

Single Dose Study of SHR4640 in Healthy Subjects